- Home
- GANX vs MCRB Comparison
GANX vs MCRB Comparison
Compare GANX & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GANX | MCRB |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.2M | 78.0M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | GANX | MCRB |
|---|---|---|
| Price | $2.00 | $7.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $7.50 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 560.0K | 33.2K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.46 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $55,180.00 | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.41 | $6.56 |
| 52 Week High | $4.34 | $29.98 |
Technical Indicators
Market Signals| Indicator | GANX | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 56.38 | 41.70 |
| Support Level | $1.65 | $7.33 |
| Resistance Level | $2.11 | $9.53 |
| Average True Range (ATR) | 0.13 | 0.42 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 83.65 | 10.39 |
Price Performance
Historical ComparisonAbout GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.